Avidity Biosciences Inc. (RNA): Price and Financial Metrics
RNA Price/Volume Stats
| Current price | $24.02 | 52-week high | $27.66 |
| Prev. close | $23.83 | 52-week low | $4.82 |
| Day low | $23.49 | Volume | 47,167 |
| Day high | $24.02 | Avg. volume | 1,152,752 |
| 50-day MA | $21.90 | Dividend yield | N/A |
| 200-day MA | $11.68 | Market Cap | 1.91B |
RNA Stock Price Chart Interactive Chart >
Avidity Biosciences Inc. (RNA) Company Bio
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.
Latest RNA News From Around the Web
Below are the latest news stories about AVIDITY BIOSCIENCES INC that investors may wish to consider to help them evaluate RNA as an investment opportunity.
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on December 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 7,100 shares of its common stock and 3,550 restricted stock units ("RSUs") to two (2) new non-executive employees under the Avidity Bioscie |
Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44™ Trial for Duchenne Muscular DystrophyAvidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive AOC 1044 data in healthy volunteers from the Phase 1/2 EXPLORE44™ clinical trial for the treatment of Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44). AOC 1044 delivered unprecedented concentrations of phosphorodiamidate morpholino oligomers (PMO) in skeletal muscle with |
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVieAvidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie are included in this Analyst Blog. |
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & MoreRegulatory and pipeline updates from Avidity Biosciences, Inc. (RNA) and BioVie (BIVI) are in the spotlight this week. |
Company News for Nov 29, 2023Companies in The News Are: ESLT,RNA,ZS,SDRL |
RNA Price Returns
| 1-mo | -2.63% |
| 3-mo | 99.50% |
| 6-mo | 393.22% |
| 1-year | 65.09% |
| 3-year | -1.19% |
| 5-year | N/A |
| YTD | 165.41% |
| 2023 | -59.22% |
| 2022 | -6.65% |
| 2021 | -6.86% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...